AAPL343.83-3.27 (-0.94%) ▼|ABBV285.99-0.40 (-0.14%) ▼|ABT102.64-0.46 (-0.45%) ▼|ACN243.40+8.24 (+3.50%) ▲|ADBE249.76+1.40 (+0.56%) ▲|AMAT416.00+20.07 (+5.07%) ▲|AMD578.44+18.18 (+3.24%) ▲|AMGN451.83+3.88 (+0.87%) ▲|AMT183.75-0.08 (-0.04%) ▼|AMZN254.60+1.50 (+0.59%) ▲|AVGO351.81+9.48 (+2.77%) ▲|AXP317.94+5.03 (+1.61%) ▲|BA167.14-1.04 (-0.62%) ▼|BAC50.85+0.17 (+0.34%) ▲|BKNG147.94-2.20 (-1.47%) ▼|BLK1,157.88+21.83 (+1.92%) ▲|BMY60.57-0.98 (-1.59%) ▼|BNY148.59+1.01 (+0.68%) ▲|BRK-B540.34-2.65 (-0.49%) ▼|C124.11+1.42 (+1.16%) ▲|CAT713.38+0.07 (+0.01%) ▲|CL91.69-0.48 (-0.52%) ▼|CMCSA21.57-0.27 (-1.24%) ▼|COF204.88+1.44 (+0.71%) ▲|COP149.06+1.10 (+0.74%) ▲|COST982.73-9.40 (-0.95%) ▼|CRM242.11+1.22 (+0.51%) ▲|CSCO110.29-1.09 (-0.98%) ▼|CVS89.95-1.18 (-1.29%) ▼|CVX229.20+0.97 (+0.43%) ▲|DE640.67+1.09 (+0.17%) ▲|DHR234.07+2.07 (+0.89%) ▲|DIS109.04-1.19 (-1.08%) ▼|DUK123.57-1.23 (-0.99%) ▼|EMR167.71+1.44 (+0.87%) ▲|FDX304.58-2.52 (-0.82%) ▼|GD354.35-0.54 (-0.15%) ▼|GE301.13+3.47 (+1.17%) ▲|GEV878.03-17.05 (-1.90%) ▼|GILD159.20+0.12 (+0.08%) ▲|GM82.48+1.94 (+2.41%) ▲|GOOG321.89+5.06 (+1.60%) ▲|GOOGL324.89+4.31 (+1.34%) ▲|GS925.17+13.40 (+1.47%) ▲|HD317.56-0.94 (-0.30%) ▼|HON219.26+0.45 (+0.21%) ▲|IBM253.22+2.97 (+1.19%) ▲|INTC95.53+1.79 (+1.91%) ▲|INTU328.19-0.26 (-0.08%) ▼|ISRG444.18-1.70 (-0.38%) ▼|JNJ271.04+2.31 (+0.86%) ▲|JPM339.30+3.51 (+1.05%) ▲|KO91.73+0.55 (+0.60%) ▲|LIN508.16-0.49 (-0.10%) ▼|LLY1,288.30+6.39 (+0.50%) ▲|LMT629.75+6.76 (+1.09%) ▲|LOW198.40+0.22 (+0.11%) ▲|LRCX253.82+12.97 (+5.39%) ▲|MA610.31+0.46 (+0.08%) ▲|MCD250.50+1.03 (+0.41%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.78+0.83 (+0.88%) ▲|META612.49-7.70 (-1.24%) ▼|MMM172.80+1.22 (+0.71%) ▲|MO72.99-0.50 (-0.68%) ▼|MRK140.93-0.89 (-0.63%) ▼|MS190.13+3.22 (+1.72%) ▲|MSFT531.01-0.32 (-0.06%) ▼|MU983.23+54.47 (+5.86%) ▲|NEE81.02-1.40 (-1.70%) ▼|NFLX61.99-0.53 (-0.85%) ▼|NKE37.15-0.41 (-1.09%) ▼|NOW150.13-4.65 (-3.00%) ▼|NVDA215.38-2.56 (-1.17%) ▼|ORCL144.54+14.01 (+10.73%) ▲|PEP132.63-0.87 (-0.65%) ▼|PFE29.45-0.35 (-1.17%) ▼|PG158.26-0.97 (-0.61%) ▼|PLTR196.81-1.92 (-0.97%) ▼|PM202.64+0.02 (+0.01%) ▲|QCOM182.97-1.20 (-0.65%) ▼|RTX195.84+1.24 (+0.64%) ▲|SBUX103.20+0.16 (+0.16%) ▲|SCHW88.76-0.54 (-0.60%) ▼|SO91.52-1.13 (-1.22%) ▼|SPG211.24-1.04 (-0.49%) ▼|T20.70-0.24 (-1.15%) ▼|TMO704.15+11.13 (+1.61%) ▲|TMUS148.08+1.25 (+0.85%) ▲|TSLA404.22-3.24 (-0.80%) ▼|TXN309.83+0.92 (+0.30%) ▲|UBER65.27-0.51 (-0.78%) ▼|UNH407.10-3.29 (-0.80%) ▼|UNP297.80-2.08 (-0.69%) ▼|UPS105.62-0.47 (-0.44%) ▼|USB59.60-0.14 (-0.23%) ▼|V400.60-1.26 (-0.31%) ▼|VZ43.18-0.75 (-1.71%) ▼|WFC83.67+1.01 (+1.22%) ▲|WMT118.77-0.55 (-0.46%) ▼|XOM182.02+2.11 (+1.17%) ▲|AAPL343.83-3.27 (-0.94%) ▼|ABBV285.99-0.40 (-0.14%) ▼|ABT102.64-0.46 (-0.45%) ▼|ACN243.40+8.24 (+3.50%) ▲|ADBE249.76+1.40 (+0.56%) ▲|AMAT416.00+20.07 (+5.07%) ▲|AMD578.44+18.18 (+3.24%) ▲|AMGN451.83+3.88 (+0.87%) ▲|AMT183.75-0.08 (-0.04%) ▼|AMZN254.60+1.50 (+0.59%) ▲|AVGO351.81+9.48 (+2.77%) ▲|AXP317.94+5.03 (+1.61%) ▲|BA167.14-1.04 (-0.62%) ▼|BAC50.85+0.17 (+0.34%) ▲|BKNG147.94-2.20 (-1.47%) ▼|BLK1,157.88+21.83 (+1.92%) ▲|BMY60.57-0.98 (-1.59%) ▼|BNY148.59+1.01 (+0.68%) ▲|BRK-B540.34-2.65 (-0.49%) ▼|C124.11+1.42 (+1.16%) ▲|CAT713.38+0.07 (+0.01%) ▲|CL91.69-0.48 (-0.52%) ▼|CMCSA21.57-0.27 (-1.24%) ▼|COF204.88+1.44 (+0.71%) ▲|COP149.06+1.10 (+0.74%) ▲|COST982.73-9.40 (-0.95%) ▼|CRM242.11+1.22 (+0.51%) ▲|CSCO110.29-1.09 (-0.98%) ▼|CVS89.95-1.18 (-1.29%) ▼|CVX229.20+0.97 (+0.43%) ▲|DE640.67+1.09 (+0.17%) ▲|DHR234.07+2.07 (+0.89%) ▲|DIS109.04-1.19 (-1.08%) ▼|DUK123.57-1.23 (-0.99%) ▼|EMR167.71+1.44 (+0.87%) ▲|FDX304.58-2.52 (-0.82%) ▼|GD354.35-0.54 (-0.15%) ▼|GE301.13+3.47 (+1.17%) ▲|GEV878.03-17.05 (-1.90%) ▼|GILD159.20+0.12 (+0.08%) ▲|GM82.48+1.94 (+2.41%) ▲|GOOG321.89+5.06 (+1.60%) ▲|GOOGL324.89+4.31 (+1.34%) ▲|GS925.17+13.40 (+1.47%) ▲|HD317.56-0.94 (-0.30%) ▼|HON219.26+0.45 (+0.21%) ▲|IBM253.22+2.97 (+1.19%) ▲|INTC95.53+1.79 (+1.91%) ▲|INTU328.19-0.26 (-0.08%) ▼|ISRG444.18-1.70 (-0.38%) ▼|JNJ271.04+2.31 (+0.86%) ▲|JPM339.30+3.51 (+1.05%) ▲|KO91.73+0.55 (+0.60%) ▲|LIN508.16-0.49 (-0.10%) ▼|LLY1,288.30+6.39 (+0.50%) ▲|LMT629.75+6.76 (+1.09%) ▲|LOW198.40+0.22 (+0.11%) ▲|LRCX253.82+12.97 (+5.39%) ▲|MA610.31+0.46 (+0.08%) ▲|MCD250.50+1.03 (+0.41%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.78+0.83 (+0.88%) ▲|META612.49-7.70 (-1.24%) ▼|MMM172.80+1.22 (+0.71%) ▲|MO72.99-0.50 (-0.68%) ▼|MRK140.93-0.89 (-0.63%) ▼|MS190.13+3.22 (+1.72%) ▲|MSFT531.01-0.32 (-0.06%) ▼|MU983.23+54.47 (+5.86%) ▲|NEE81.02-1.40 (-1.70%) ▼|NFLX61.99-0.53 (-0.85%) ▼|NKE37.15-0.41 (-1.09%) ▼|NOW150.13-4.65 (-3.00%) ▼|NVDA215.38-2.56 (-1.17%) ▼|ORCL144.54+14.01 (+10.73%) ▲|PEP132.63-0.87 (-0.65%) ▼|PFE29.45-0.35 (-1.17%) ▼|PG158.26-0.97 (-0.61%) ▼|PLTR196.81-1.92 (-0.97%) ▼|PM202.64+0.02 (+0.01%) ▲|QCOM182.97-1.20 (-0.65%) ▼|RTX195.84+1.24 (+0.64%) ▲|SBUX103.20+0.16 (+0.16%) ▲|SCHW88.76-0.54 (-0.60%) ▼|SO91.52-1.13 (-1.22%) ▼|SPG211.24-1.04 (-0.49%) ▼|T20.70-0.24 (-1.15%) ▼|TMO704.15+11.13 (+1.61%) ▲|TMUS148.08+1.25 (+0.85%) ▲|TSLA404.22-3.24 (-0.80%) ▼|TXN309.83+0.92 (+0.30%) ▲|UBER65.27-0.51 (-0.78%) ▼|UNH407.10-3.29 (-0.80%) ▼|UNP297.80-2.08 (-0.69%) ▼|UPS105.62-0.47 (-0.44%) ▼|USB59.60-0.14 (-0.23%) ▼|V400.60-1.26 (-0.31%) ▼|VZ43.18-0.75 (-1.71%) ▼|WFC83.67+1.01 (+1.22%) ▲|WMT118.77-0.55 (-0.46%) ▼|XOM182.02+2.11 (+1.17%) ▲|
11.5 C
New York
Thursday, October 29, 2026

Tag: loss

newsFORsourcecompanycontentinformationreleases1market

What the September Jobs Report Really Changes for Global Markets

HO CHI MINH CITY, Vietnam, Oct. 26, 2026 /PRNewswire/ -- JustMarkets recently released a comprehensive analysis on the implications of the latest US employment...

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for...

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for...

From loss to lasting impact: More than $4.5M raised by the Orchid Women’s Health Initiative to change women’s health care in Nova Scotia

HALIFAX, NS, Oct. 25, 2026 /CNW/ -- What began as a tribute to a beloved friend has grown into a multimillion-dollar movement transforming women's...

COP17 welcomes Value Nature Fund’s approach to mobilizing private capital for nature

Fondaction and Triodos Bank demonstrate at COP17 how innovative finance can accelerate the implementation of global biodiversity goalsMONTREAL, Oct. 25, 2026 /CNW/ -- At...

Borr Drilling Limited – Prospector 5 Rig Incident

HAMILTON, Bermuda, October 25, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE and OSE: BORR) ("Borr Drilling") confirms that an incident occurred at approximately 20:37 local...

Stadium-sized support for wildlife at WWF-Canada’s biggest BC Place Climb for Nature

 The third annual event raised $122,000, pushing 2026's national Climb for Nature total to $1.6 million VANCOUVER, BC, Oct. 24, 2026 /CNW/ -- A record...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

In HelloNation, Insurance Expert Devery Prince Breaks Down Affordable Insurance in Alaska

The Article Explains How Choosing the Right Coverage Matters More for Alaska Residents Than Simply Finding the Lowest Premium.ANCHORAGE, Alaska, Oct. 24, 2026 /PRNewswire/...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk...

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as...

Quest Diagnostics Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Unauthorized Access to Patient Records

National class action law firm offers free, confidential case evaluations to Quest Diagnostics patients and others whose information may have been exposed.SECAUCUS, N.J., Oct....

Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges

VANCOUVER, BC, Oct. 23, 2026 /CNW/ -- Stock Preachers News Commentary - Stocks closed a volatile earnings week with a split verdict: the Dow gained...

METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR THIRD QUARTER 2026

ATLANTA, Oct. 23, 2026 /PRNewswire/ -- MetroCity Bankshares, Inc. ("MetroCity" or the "Company") (NASDAQ: MCBS), holding company for Metro City Bank (the "Bank"), today...

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie’s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn’s Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLoss

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers